Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compared to other calcium channel blocking agents, nimodipine exhibits greater effects on cerebral circulation than on peripheral circulation. Nimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm.
For use as an adjunct to improve neurologic outcome following subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms by reducing the incidence and severity of ischemic deficits.
Yale University School of Medicine (Connecticut Mental Health Center), New Haven, Connecticut, United States
The University of Alabama at Birmingham, Birmingham, Alabama, United States
Brain and Spine Neurological Institute, Phoenix, Arizona, United States
Community Regional Medical Center, Fresno, California, United States
Clinical Research Unit, Montréal, Canada
Aculty of Medicine,Zagazig University, Zagazig, El Sharkia, Egypt
Faculty of Medicine,Zagazig University, Zagazig, Zagazig, Elsharkia,egypt, Egypt
2ndAffiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Toronto Western Hospital, Toronto, Ontario, Canada
Medical University of Vienna, Vienna, Austria
Medical University of Vienna, Vienna, Austria
ِAssiut University Hospital, Assiut, Egypt
Rijnstate Hospital, Arnhem, Gelderland, Netherlands
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.